397 results on '"Bushby K"'
Search Results
2. Six minute walk test in type III spinal muscular atrophy: A 12 month longitudinal study
3. 170th ENMC International Workshop: Bone protection for corticosteroid treated Duchenne muscular dystrophy. 27–29 November 2009, Naarden, The Netherlands
4. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France
5. P.122 Comparative safety and efficacy of different corticosteroid regimens in boys with Duchenne muscular dystrophy: results of a randomized controlled trial
6. LGMD: EP.182 Quality of life in dysferlinopathy can be good despite poor function
7. DMD/BMD - GENETICS: EP.116 Establishing clinical and genetic characteristics in young, glucocorticoid-naïve boys with Duchenne muscular dystrophy: the FOR DMD study
8. P.162 - Does the performance of upper limb capture functional variations in dysferlinopathy?
9. P.163 - Examining the relationship between Dixon quantitative MRI and physiotherapy functional outcome measures in dysferlinopathy
10. P.160 - Is cardiac dysfunction a feature of dysferlinopathy? Data from the clinical outcome study of dysferlinopathy
11. P.161 - North Star Assessment for dysferlinopathy: Longitudinal performance in the clinical outcome study of dysferlinopathy
12. P.137 - Corticosteroid treatment in early-onset lamin A/C related muscular dystrophies
13. P.135 - First results from the international LMNA-related congenital and childhood onset muscular dystrophy retrospective natural history study
14. P.111 - Patient's perception around disease progression and influential factors in spinal muscle atrophy
15. P.115 - Failure to attend neuromuscular clinic appointments: reasons and interventions
16. P.5 - DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UK
17. OD11 - The MYO-SEQ project: application of exome sequencing technologies to 1000 patients affected by limb-girdle weakness of unknown origin
18. OD17 - Clinical research activity in the Newcastle MRC Centre for Neuromuscular Disease
19. OD06 - An audit on the reasons why patients failed to attend the Newcastle University Trust Hospitals’ Neuromuscular Clinics, at the John Walton Muscular Dystrophy Research Centre, and the actions taken
20. OD05 - Audit of unplanned hospital admissions for patients with neuromuscular disorders in the North East
21. OD01 - Clinical characterisation of a large international congenital titinopathy cohort
22. D37 - Vision DMD: A drug development program for vamorolone in Duchenne muscular dystrophy
23. D31 - Telethonin gene mutations detected by next generation sequencing
24. D29 - Semi-quantitative muscle MRI in dysferlinopathy patients: pattern recognition and implications for clinical trials
25. D20 - Development of a robust disease specific functional measure suitable for trials in ambulant and non-ambulant individuals with dysferlinopathy
26. D16 - Quantitative magnetic resonance imaging of the skeletal muscle in a multi-center dysferlinopathy study: 1-year follow-up
27. D13 - Myofibrillar myopathy phenotype due to recessive mutations in MEGF10
28. D12 - Clinical outcome study for dysferlinopathy: Sensitivity of outcome measures over one-year
29. Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England.
30. Calpainopathy presenting as foot drop in a 41 year old
31. P.260 - Mobility shift of beta-dystroglycan combined with reduced laminin alpha2 expression is a marker of genetic defects in the GMPPB gene
32. P.226 - Vision DMD: Vamorolone drug development program for Duchenne muscular dystrophy
33. P.116 - A comparative study of care and support for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosis
34. P.126 - Adult Duchenne population: A growing population
35. P.118 - Growth patterns and fractures in boys with Duchenne muscular dystrophy: Insights from over 800 boys in the UK North Star cohort
36. P.49 - Revised Hammersmith scale for spinal muscular atrophy: Longitudinal changes over six and twelve months in a large international cohort
37. P.7 - Clinical outcome study for dysferlinopathy: One-year follow-up
38. S.O.2 - Analysis of a large international cohort confirms that recessively inherited loss-of-function TTN mutations cause prenatal or infant-onset muscle disease, often complicated by early cardiorespiratory involvement
39. P.8 - Development of a robust disease specific functional measure suitable for trials in ambulant and non-ambulant individuals with dysferlinopathy
40. G.P.404 - The frequency and characterisation of cardiac involvement in female carriers of BMD or DMD: A cross sectional analysis
41. G.P.387 - Overview of morbidity, mortality and survival in Duchenne muscular dystrophy in the North East of England
42. G.P.376 - Collaboration in NeurOmics: Enabling effective data-sharing and maximising impact in neuromuscular disease
43. G.P.377 - NeurOmics: EU-funded-omics research for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases
44. G.P.345 - A novel STIM1 mutation at p.340 causes tubular aggregate myopathy with miosis without additional features of Stormorken syndrome
45. G.P.284 - The TREAT-NMD Advisory Committee for Therapeutics (TACT): An innovative de-risking model to foster orphan drug development
46. G.P.285 - TREAT-NMD (translational research in Europe, assessment and treatment for neuromuscular disorders)
47. G.P.272 - Eight novel UK families further expand current knowledge on GMPPB-gene related dystroglycanopathies
48. G.P.279 - Congenital muscular dystrophies in the UK population: Update of clinical and molecular spectrum of patients diagnosed over a 12-year period
49. G.P.254 - VISION – DMD: Drug development of VBP15, an experimental steroid-like drug for DMD
50. G.P.243 - First drug registry in Duchenne muscular dystrophy (DMD) to assess Translarna (Ataluren) use, safety, and effectiveness in routine clinical practice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.